Telenav Inc. (Nasdaq: TNAV) Rises on Lawsuit Settlement

Telenav, Inc.– Nasdaq: TNAV

Telenav, Inc. announced that it has settled a lawsuit accusing the firm of patent infringement brought by Vehicle IP, LLC. The one-time payment of $8 million will have a material impact on 2016 Q4 results. Telenav, Inc. is a provider of location based services including voice guided navigation, on mobile phones.

Telenav Inc. trades on the Nasdaq under the ticker TNAV. News of the settlement sent TNAV gapping up from its Thursday close of $7. Today TNAV opened at $8.10 and reached as high as $8.70 on heavy volumes.

In the press release Michael Strambi, Chief Financial Officer of Telenav stated “We experienced higher than expected revenue for the December quarter, which was driven by increases in both our Auto and Advertising businesses. However, operating expenses were greater than anticipated due to the one-time settlement and license fee.  At December 31, 2016, we had cash and short-term investments of $103.7 million.  The payment for the settlement will occur during January 2017.  As of September 30, 2016, we had accrued a liability of $850,000 related to the case, so the settlement’s impact on the December quarter will be reduced by that accrued amount.  We will provide our full financial results on our earnings call scheduled for January 31st.” The company will report results for the second quarter fiscal 2017 on Tuesday, January 31, 2017 with an investor conference call and live webcast at 2:00 p.m. PT (5:00 p.m. ET). To access the conference call, dial 877-795-3648 (toll-free, domestic only) or 719-325-4755 (domestic and international toll) and enter pass code 5663996.

Telenav Inc. is followed by four firms. All four rate TNAV as a “Strong Buy” with a consensus price target of $10.75. For 2016 Telenav Inc reported an EPS loss of $0.85 down from their reported 2015 EPS loss of $0.58. However, sales improved during that period. In 2015 holders of TNAV saw reported revenues of $160.2 million and in 2016 reported revenues were $183.3 million

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/13/2017
Ticker Symbol DXCM
Last Price a/o 10:22 AM EST  $                      8.23
Average Volume 82,200
Market Cap $297 million
Sales $181.5 million
Shares Outstanding 42.5 million
Share Float 26.53 million
Shortable Yes
Optionable Yes
Inside Ownership 4.40%
Short Float 1.22%
Short Interest Ratio 3.95
Quarterly Return 21.95%
YTD Return -0.71%
Year Return 35.40%

Ariad Pharmaceuticals (Nasdaq: ARIA) Agrees to $5.2 Billion Buy-out

Ariad Pharmaceuticals, Inc. – Nasdaq: ARIA

Takeda Pharmaceutical Company Inc. has agreed to purchase Cambridge, MA-based Ariad Pharmaceuticals for $24 per share. Ariad’s shares, traded on the Nasdaq under ticker ARIA, closed Friday at $13.74 and shot up to an intraday high of $23.81. The $5.2 Billion deal represents a 75% premium over the Friday closing price.

ARIAD Pharmaceuticals, Inc. is focused on discovering, developing and commercializing precision therapies for patients with rare cancers. ARIAD is working on new medicines to advance the treatment of rare forms of chronic and acute leukemia, lung cancer and other rare cancers. According to its website, Takeda conducts activities according to the corporate mission to “strive towards better health for people worldwide through leading innovation in medicine.”

Alexander J. Denner, Ph.D., Chairman of the ARIAD Board of Directors, said: “This transaction is a great outcome for ARIAD shareholders and brings hope to improve the lives of many cancer patients. It has been a pleasure to work with our outstanding management team and, on behalf of the board of directors, I extend our deepest gratitude to everyone at ARIAD for their unrelenting dedication.”

Ariad Pharmaceuticals is covered by nine firms. Five gave ARIA a rating of “Strong Buy”, two rated ARIA a “Hold”, and two rated ARIA a “Sell”. Their consensus price target was $13. While ARIA has never reported a profit, it sales have done well. In 2011 Ariad Pharmaceuticals reported sales of $25.3 million but in 2015 Ariad reported sales of $118.8 million.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/9/2017
Ticker Symbol ARIA
Last Price a/o 11:32 AM EST  $                    23.75
Average Volume 6.5 million
Market Cap $2.6 Billion
Sales $186.2 million
Shares Outstanding 189.4 million
Share Float 187.7 million
Shortable Yes
Optionable Yes
Inside Ownership 0.20%
Short Float 17.26%
Short Interest Ratio 13.45
Quarterly Return 2.92%
YTD Return 10.45%
Year Return 161.22%

EnteroMedics Inc. (Nasdaq: ETRM) Makes Larges Gains in Pre-Market

EnteroMedics Inc.– Nasdaq: ETRM

Shares of MN-based EnteroMedics Inc. are up over 80% in pre-market trading on heavy volume. Shares are traded on the Nasdaq under the ticker symbol ETRM. ETRM closed at $2.09 on Wednesday, $3.97 on Thursday, and have traded as high as $7.62.

EnteroMedics® Inc. develops therapies for obesity. It has developed vBloc® vagal blocking therapy, a patented therapeutic approach to treat a range of gastrointestinal and metabolic diseases. vBloc® is a weight loss treatment that addresses the growing global health crises associated with obesity and its co-morbidities, such as diabetes and hypertension.

vBloc® Therapy, delivered by a pacemaker-like device called the Maestro® Rechargeable System, controls both hunger and fullness by blocking the primary nerve which regulates the digestive system. The Maestro Rechargeable System has received Food and Drug Administration (FDA) approval as well as CE Mark in Europe, and has been listed on the Australian Register of Therapeutic Goods (ARTG) by the Therapeutic Goods Administration (TGA) for supply in Australia.

Price action seems to be motivated by news that MedStar Health in Maryland and Roper St. Francis in South Carolina, both vBloc institutes, have implanted vBloc Neurometabolic therapies.

EnteroMedics Inc. has no reported sales. Only one firm follows ETRM and rates it as a “Strong Buy”.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/6/17
Ticker Symbol ETRM
Last Price a/o 8:25 AM EST $5.32
Average Volume 10.46 milion
Market Cap $11.51 million
Sales $0.79 million
Shares Outstanding 2.9 million
Share Float 2.38 million
Shortable No
Optionable Yes
Inside Ownership
Short Float
Short Interest Ratio
Quarterly Return 2919.00%
YTD Return 98.50%
Year Return 120.56%

Today’s Nasdaq Small-cap Winners $AKAO $GBT $EXAS $FOLD $BCRX

Today’s top Nasdaq Small-cap Winners $AKAO $EXAS $GBT $FOLD $BCRX

AKAO – Achaogen, Inc. +14.46%

Intraday – http://elite.finviz.com/publish/010417/AKAOc0i3l1835.png

Daily – http://elite.finviz.com/publish/010417/AKAOccdl18400326.png

 

EXAS – Exact Sciences Corp. +11.48%

Intraday –  http://elite.finviz.com/publish/010417/EXASc0i3l1836.png

Daily –  http://elite.finviz.com/publish/010417/EXASccdl18411282.png

GBT – Global Blood Therapeutics, Inc. +10.84%

Intraday –  http://elite.finviz.com/publish/010417/GBTc0i3l1837.png

Daily – http://elite.finviz.com/publish/010417/GBTccdl18426442.png

FOLD – Amicus Therapeutics, Inc. +9.75%

Intraday –  http://elite.finviz.com/publish/010417/FOLDc0i3l1838.png

Daily –  http://elite.finviz.com/publish/010417/FOLDccdl18420773.png

BCRX – BioCryst Pharmaceuticals, Inc. +8.18%

Intraday –  http://elite.finviz.com/publish/010417/BCRXc0i3l1843.png

Daily –  http://elite.finviz.com/publish/010417/BCRXc0dl1844.png

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

Our Picks for 2016 – If We Had a Time Machine

As we say goodbye to 2016, let’s take a look at some of the best performing Nasdaq small cap performances. The stocks below are our choices for what we would have bought if we could just borrow someone’s time machine. If you happen to have one, we promise that we will return it in better shape than we got it!

  1. Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) – This biotechnology firm leads our list with a whopping return of excess of 425% for 2016. Four analysts cover CRBP – all rate it “Strong Buy”. Consensus price target is $18.
  2. Oclaro, Inc. (Nasdaq: OCLR) – OCLR manufactures optical oriented internet infrastructure equipment. YTD returns are over 170%. Ten analysts cover OCLR – nine rate it as a “Strong Buy” while one rates it as a “Hold”. Consensus price target is $12.
  3. Hudson Technologies Inc. (Nasdaq: HDSB) – Hudson Technologies specializes in refrigeration. Cold must be good business – HDSN is up almost 175% YTD. All three analysts that cover the stock give it a “Strong Buy”. Consensus price target is $9.50.
  4. Energous Corporation (Nasdaq: WATT) – Energous develops wireless charging technology. Investors seem to like the idea as WATT is up over 130% YTD. All three analysts that cover WATT give it a “Strong Buy”. Consensus price target is $15.50.
  5. TTM Technologies Inc. (Nasdaq:TTMI) – TTM Technologies designs and manufactures circuit boards. It may not sound sexy, but investors loved TTMI in 2016 – sending it up almost 120%. Three analysts cover TTMI – two rate it “Strong Buy” and one rates it a “Buy”. Consensus price target is $15.00.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

Immunomedics, Inc. (NASDAQ:IMMU)

Merus N.V. (Nasdaq: MRUS) Up Big on Collaboration Agreement with Incyte Corp (Nasdaq: INCY)

Merus N.V.; Nasdaq: MRUS

Shares of Netherlands-based Merus N.V. are up over 45% today on heavy volumes. Traded on the Nasdaq under ticker symbol MRUS, shares closed yesterday at $14.15 but today MRUS has hit an intraday high of $22.19 on news of a collaboration agreement with Incyte Corporation (Nasdaq: INCY). 

Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics with the goal of treating and potentially curing cancer patients. The global, strategic collaboration agreement focuses on the research, discovery and development of bispecific antibodies utilizing Merus’ proprietary Biclonics® technology platform. The Collaboration and License Agreement grants Incyte the exclusive rights for up to eleven bispecific antibody research programs, including two of Merus’ current preclinical immuno-oncology discovery programs. 

From the joint press release:

“This transformative, global collaboration further underscores the potential of Merus’ Biclonics® technology platform and establishes a strong relationship with Incyte, a leader in innovative drug development,” said Ton Logtenberg, Ph.D., Chief Executive Officer of Merus. “We look forward to expanding our pipeline under this agreement, as we efficiently exploit our preclinical discovery engine and progress our most advanced, proprietary assets in the clinic.”

MRUS was trading below $8.00 in June. Three analysts follow MRUS and all have assigned MRUS a rating of “Strong Buy”.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

Ticker Symbol MRUS
Last Price a/o 1:41 PM EST  $             21.00
Average Volume 6,260
Market Cap $233.3 million
Sales $3.6 milion
Shares Outstanding 16.49 million
Share Float 13.25 million
Shortable Yes
Optionable No
Inside Ownership
Short Float 0.08%
Short Interest Ratio 1.73
Quarterly Return 32.74%
YTD Return 40.94%
Year Return

Century Aluminum Company (Nasdaq: CENX) Rises Steadily in Daily Trading

Century Aluminum Company; Nasdaq: CENX

Shares of Century Aluminum Company closed at $8.48 yesterday, opened a few cents higher, and have been on a steady climb throughout the day. At the time of this writing (2:24 PM EST) CENX was trading around today’s high of $9.50.

Century Aluminum Company is a global producer of primary aluminum and operates aluminum reduction facilities in the United States and Iceland. Century Aluminum Company operates three U.S. aluminum smelters, in Hawesville, Kentucky (Hawesville), Robards, Kentucky (Sebree) and Mt. Holly, South Carolina (Mt. Holly), and one smelter in Grundartangi, Iceland (Grundartangi). The company is traded on the Nasdaq under the ticker CENX.

Four well known investments banks cover shares of CENX and all provide a price target ($7) below current trading levels. All also have a neutral rating of “Hold” on CENX. Further investigation into breaking news reports produced no information that might suggest a reason for the stock’s steady rise today.

Sales for Century Aluminum Company have risen from $1.36 Billion (2011) to $1.95 Billion in 2015. However investors should also note that last year CENX produced an EPS loss of $0.55. Also of note is the Century Aluminum’s CFO recently left the company.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

Ticker Symbol CENX
Last Price a/o 2:41 EST  $               9.53
Average Volume 1.99 million
Market Cap $756 million
Sales $1.36 Billion
Shares Outstanding 89.1 million
Share Float 49.3 million
Shortable Yes
Optionable Yes
Inside Ownership 0.20%
Short Float 23.80%
Short Interest Ratio 5.88
Quarterly Return 40.33%
YTD Return 92.08%
Year Return 122.25%

Versartis Inc, (Nasdaq: VSAR) Moves Higher

Versartis, Inc – OTCQB: VSAR

Shares of Versartis, Inc. are moving higher in early trading on heavy volume. The Menlo, CA-based company trades on the Nasdaq under ticker symbol VSAR. Versartis is an endocrine-focused biopharmaceutical company that is developing a form of recombinant human growth hormone to treat growth hormone deficiency (GHD) in children and adults.

Unconfirmed reports suggest that Versartis, Inc has filed a “Confidential Treatment Report” with the SEC. Such a filing would allow for information in an SEC filing to be kept secret, if leaking such information could cause material or financial harm to the company or a business partner.

Shares of VSAR closed yesterday at $13.30 and are trading at $15.10 at 11:22 EST. Volumes are heavy and trader chat rooms are active. According to information gathered from the Nasdaq website, four firms follow VSAR – one rating it as a “Hold” and three giving it a “Strong Buy”. The consensus price target is $23.50.

Always perform your own due diligence before making any decisions regarding the buy or sale of any stock. All information or data is provided without any guarantee of its accuracy.

Ticker Symbol VSAR
Last Price a/o 11:27 EST  $             14.85
Average Volume 181,260
Market Cap $469.89
Sales
Shares Outstanding 35.33 million
Share Float 34.57 million
Shortable Yes
Optionable Yes
Inside Ownership 0.90%
Short Float 2.43%
Short Interest Ratio 4.64
Quarterly Return 3.22%
YTD Return 7.34%
Year Return 11.30%

 

Southwest Banc Corp Inc (Nasdaq: OKSB) Announces Merger

Southwest Bancorp, Inc – Nasdaq: OKSB

Simmons First National Corporation (Nasdaq: SFNC) and Southwest Bancorp, Inc. (Nasdaq: OKSB) have announced today that they will merge. Simmons will acquire SouthWest Bancorp, Inc. for approximately $564.4 million. This news came an hour after Illinois investment bank Hovde Group downgraded OKSB from “Outperform” to “Market Perform”. News of the merger sent investors into a buying mode that sent the shares to gains of over 20% in mid-day trading.

From the Southwest Bancorp, Inc press release:

Under the terms of the Agreement, each outstanding share of common stock and equivalents of SBI will be converted into the right to receive 0.3903 shares of the Company’s common stock and $5.11 in cash, all subject to certain conditions and potential adjustments.  Completion of the transaction is expected in the third quarter of 2017 and is subject to certain closing conditions, including approval by the shareholders of both SBI and the Company, as well as customary regulatory approvals.

EPS for OKSB were $0.64 in 2012 and rose to $0.90 in 2015. However sales have dropped since 2012 – from $93.2 million to $74.5 million. OKSB has traded as high as $28.95 but fell back to $28.50 at the time of this writing.

Simmons is a financial holding company, headquartered in Pine Bluff, AR., with financial operations throughout Arkansas, Kansas, Missouri and Tennessee. Simmons offers comprehensive financial solutions delivered with a client-centric approach. The company’s common stock trades on the Nasdaq under the symbol “SFNC.”

Always perform your own due diligence before making any decisions regarding the buy or sale of any stock. The below data is provided without any guarantee of its accuracy.

 

Global Eagle Entertainment (Nasdaq: ENT) Soars on Contract Extension with Southwest Airlines

Market Mover Alert! Global Eagle Entertainment Inc. – Nasdaq: ENT

Shares, and volumes, of Global Eagle Entertainment have climbed on news of a new contract with SouthWest Airlines (NYSE: LUV). Traded on the Nasdaq under ticker symbol ENT, shares closed on Tuesday at $6.44 and have traded today at a high of $8.05. Global Eagle Entertainment has offices globally and is headquartered in Marina del Ray, CA.

The extension takes the current contract from 2020 to 2025. Global Eagle Entertainment provides the connectivity system and services for inflight entertainment to SouthWest Airlines. According to press reports, the contract extension is expected to provide a lift to ENT price levels as it has been floundering against the Zacks Internet Content industry index for the past six months. The company has experienced good news in 2016, receiving the Inflight Award for “Best Handheld Wireless IFE System”. Global Eagle Entertainment also boasts a distribution agreement with Premiership Rugby, and an agreement to supply an integrated streaming platform to Saudi Arabian Airlines.

Four firms cover ENT with one assigning a rating of “Hold”, one “Buy”, and two give a “Strong buy”. Analyst price targets range from $16 to $22. Global Eagle Entertainment sales have increased each year. In 2012, sales were $69.2 million and in 2015 they reported sales of $426 million. EPS, though still negative, have improved from a loss of $2.24 EPS in 2012 to a loss of $0.78 EPS in 2015.

Always perform your own due diligence before making any decisions regarding the buy or sale of any stock. The below data is provided without any guarantee of its accuracy.

 

Ticker Symbol ENT
Last Price a/o 10:20 EST  $                     7.64
Average Volume 358,540
Market Cap $547.7 million
Sales $486.2 million
Shares Outstanding 85 million
Share Float 83 million
Shortable Yes
Optionable Yes
Inside Ownership 0.70%
Short Float 4.59%
Short Interest Ratio 10.62
Quarterly Return -21.46%
YTD Return -34.75%
Year Return -35.54%